Dual Thrombolytic Regimen (tPA + HisproUK)
Ischemic Stroke
Key Facts
About Thrombolytic Science International
Thrombolytic Science International is pioneering a sequential dual thrombolytic regimen combining a low dose of tissue plasminogen activator (tPA) with its proprietary compound, mutant prourokinase (HisproUK), to treat acute ischemic stroke and heart attack. The approach aims to be safer and more efficacious than current standards of care by enabling administration on suspicion of a clot, potentially in an ambulance, thereby reducing critical time-to-treatment. The company has advanced its lead program into Phase 2 trials for both stroke and AMI, supported by a strong IP portfolio and a seasoned leadership team with deep expertise in vascular medicine. TSI represents a potentially disruptive player in the cardiovascular and cerebrovascular therapeutic space by addressing a major unmet need in emergency reperfusion therapy.
View full company profileAbout Thrombolytic Science International
Thrombolytic Science International is pioneering a sequential dual thrombolytic regimen combining a low dose of tissue plasminogen activator (tPA) with its proprietary compound, mutant prourokinase (HisproUK), to treat acute ischemic stroke and heart attack. The approach aims to be safer and more efficacious than current standards of care by enabling administration on suspicion of a clot, potentially in an ambulance, thereby reducing critical time-to-treatment. The company has advanced its lead program into Phase 2 trials for both stroke and AMI, supported by a strong IP portfolio and a seasoned leadership team with deep expertise in vascular medicine. TSI represents a potentially disruptive player in the cardiovascular and cerebrovascular therapeutic space by addressing a major unmet need in emergency reperfusion therapy.
View full company profileTherapeutic Areas
Other Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| dl-3-n-Butylphthalide (NBP) Soft Capsules | cspc-pharmaceutical | Phase 3 |
| MultiStem | Athersys | Phase 3 |
| IQool™ System | BrainCool | Clinical Evaluation |
| itMSCs + itNSCs | Stemedica Cell Technologies | Research |
| BXT-25 | BioXyTran | Preclinical |
| Ischemic Stroke Program | CHS Pharma | Pre-clinical |
| 3K3A-APC | ZZ Biotech | Phase 2/3 |
| Ischemic Stroke Device(s) | Infinity Neuro | Pre-clinical |
| THDG3 | DeckTherapeutics | Pre-clinical |
| Prometheus-based Gene Therapy | Remedium Bio | Pre-clinical |
| iNstroke Catheters | iVascularU | Commercial |
| Neural Stem Cell Therapy for Stroke | Neoneuron | Pre-clinical |